WILMINGTON — CorriXR Therapeutics has unveiled preliminary data from a study that shows that its gene-editing technology can help treat solid cancer tumors as it eyes manufacturing agreements in the future. The life science startup, which spun out of the ChristianaCare Gene Editing Institute in 2022, has published preclinical data in “Molecular Therapy Oncology” that Already a subscriber? Log in

To continue reading this article ...

Subscribe to Delaware Business Times right now and get access to subscriber-only content like this article.

Plus get 24 issues of DBT, special bonus issues, and discounted registration for our in-person events. Learn More and Subscribe Today

See Full Page